Summary & Overview
HCPCS M0075: Cellular Therapy Processing and Provision
HCPCS Level II code M0075 designates cellular therapy services, covering the handling, processing, or provision of cellular products used in therapeutic treatments. This code is relevant nationally as cellular therapies expand across oncology, immunology, and regenerative medicine, driving demand for standardized billing and payer coverage policies. Clear coding for cellular therapy affects facility billing workflows, reimbursement consistency, and access to advanced treatments.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage considerations, common billing modifiers, and clinical context for when M0075 is used. The publication summarizes typical sites of service and service line implications, highlights coding relationships, and outlines where input was not available.
What readers will learn: benchmarks and typical billing contexts for cellular therapy claims using M0075, payer coverage patterns and policy considerations, and practical clinical settings where the code applies. Data not provided in the input is identified as such. The content is national in scope and intended for billing managers, revenue cycle professionals, and policy analysts tracking advanced therapy reimbursement.
Billing Code Overview
HCPCS Level II code M0075 describes cellular therapy services. This code pertains to the processing, handling, or provision of cellular therapy products used in therapeutic treatments. The service type is cellular therapy provision/processing. The typical site of service for cellular therapy includes specialized outpatient infusion centers, hospital-based infusion or transplant units, and designated cell-processing laboratories that manage collection, preparation, and administration of cellular products.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient with relapsed diffuse large B-cell lymphoma is evaluated for autologous cellular therapy using harvested and processed peripheral blood stem cells. The patient presents to an outpatient apheresis unit for cell collection, then to a specialized cell-processing laboratory for manipulation and cryopreservation, and later to an inpatient hematology/oncology unit for high-dose chemotherapy and reinfusion of the cellular product. The clinical workflow includes: pre-procedure eligibility assessment and informed consent; vascular access placement (central venous catheter or large-bore peripheral access) for apheresis; mobilization of stem cells with granulocyte-colony stimulating factor (G-CSF) with or without plerixafor; apheresis collection sessions to obtain the cellular product; cell processing, testing, and cryopreservation in a licensed cell-processing facility; storage and release testing; conditioning regimen administration; and reinfusion of the cellular therapy product with post-infusion monitoring for infusion reactions, engraftment, and infectious complications. Typical sites of service include outpatient apheresis centers, hospital-based cell-processing laboratories, and inpatient bone marrow transplant units. The patient scenario may require coordination with blood bank, pathology, and specialty pharmacy services for product tracking, chain-of-custody documentation, and payer authorization for cellular therapy services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |